Contents
pdf Download PDF
pdf Download XML
95 Views
20 Downloads
Share this article
Original Article | Volume 12 Issue 11 (November, 2026) | Pages 481 - 490
Nebulised 0.5% ropivacaine versus 2% lidocaine: haemodynamic responses to intubation and extubation
 ,
 ,
 ,
1
Rajalakshmi Medical College Hospital and Research Institute, Sriperumbudur, Tamil Nadu, India
2
Meenakshi Medical College Hospital and Research Institute, Kanchipuram, Tamil Nadu, India
3
Sirkazhi Government Hospital, Mayiladuthurai District, Tamil Nadu, India
4
Jawaharlal Institute of Postgraduate Medical Education and Research, Puducherry,India,
Under a Creative Commons license
Open Access
Received
Aug. 15, 2026
Revised
Oct. 25, 2026
Accepted
Nov. 6, 2026
Published
Nov. 20, 2026
Abstract
Background: Laryngoscopy, tracheal intubation and extubation raise heart rate and blood pressure. Lidocaine acts briefly, whereas ropivacaine acts longer and may still anaesthetise the airway at emergence. We compared the two drugs given by nebulisation.Materials and Methods: In this double-blind randomised study, 60 ASA physical status I–II adults undergoing elective surgery of less than 2 hours under general anaesthesia received pre-induction nebulisation with 5 mL of 0.5% ropivacaine (Group R, n = 30) or 2% lidocaine (Group L, n = 30). Heart rate (HR), systolic (SBP), diastolic (DBP) and mean arterial pressure (MAP) were recorded from baseline to 2 minutes after extubation, with cough at extubation and sore throat at 12 hours.Results: Patient characteristics and baseline values did not differ between groups. At intubation, all values were lower in Group L than in Group R (median HR 70 vs 79 beats/min, p < 0.001; SBP 118 vs 123 mmHg, p = 0.001; DBP 68 vs 72 mmHg, p = 0.006; MAP 84.5 vs 90 mmHg, p = 0.003). The groups did not differ at anaesthetic withdrawal or eye opening. At extubation the pattern reversed, with lower values in Group R (HR 84 vs 88 beats/min, p = 0.038; MAP 97 vs 101 mmHg, p = 0.005), and the difference widened 2 minutes later (HR 86 vs 90 beats/min, SBP 132 vs 139 mmHg, MAP 97.5 vs 103.5 mmHg; all p < 0.001). Cough at extubation occurred in 6 patients (20%) in Group R and 15 (50%) in Group L (difference 30 percentage points, 95% CI 6 to 50; p = 0.015), and sore throat in 2 (6.7%) and 12 (40%), respectively (difference 33 percentage points, 95% CI 12 to 52; p = 0.005). No patient required treatment for hypotension or bradycardia.Conclusions: Nebulised 2% lidocaine better attenuated the intubation response, whereas 0.5% ropivacaine better attenuated the extubation response and reduced emergence cough and sore throat.
Keywords
INTRODUCTION
Laryngoscopy and tracheal intubation stimulate receptors in the pharynx, larynx and trachea and provoke a sympathetic response, with rises in heart rate, blood pressure and plasma catecholamines [1, 2]. In patients with ischaemic heart disease, hypertension or cerebrovascular disease it can precipitate myocardial ischaemia, arrhythmias or cerebral events, and haemodynamic instability is among the most common serious complications of intubation [3]. Emergence and airway extubation produce a similar haemodynamic response, often accompanied by coughing [4, 5], and postoperative sore throat affects up to 62% of patients after general anaesthesia [6–8]. Many drugs have been used to blunt the intubation response, including intravenous lidocaine [2, 9] and nebulised dexmedetomidine [10–12]; intravenous lidocaine, dexmedetomidine and remifentanil have similarly been used to reduce emergence cough [4, 13–15]. Topical airway anaesthesia is an alternative that acts directly on the receptors involved: it reduces coughing at emergence [16, 17], and laryngotracheal ropivacaine attenuates the blood pressure response to intubation [18]. Nebulisation delivers local anaesthetic simply and non-invasively to the whole upper airway, and only a fraction of the dose is absorbed [19]; nebulised agents have also been used to prevent sore throat [20]. Nebulised lidocaine attenuates the intubation response [21, 22], but its short duration of action limits any effect at the end of surgery. Ropivacaine is a long-acting amide local anaesthetic with less cardiotoxicity and central nervous system toxicity than bupivacaine [23, 24], so a single pre-induction dose might still anaesthetise the airway at emergence. Laryngotracheal ropivacaine has reduced emergence cough [5], and nebulised ropivacaine has attenuated intubation and extubation responses compared with saline [25, 26]. Direct comparisons with lidocaine are few, have used different ropivacaine concentrations and have given inconsistent results [25, 27]. The aim of this study was to compare nebulised 0.5% ropivacaine and 2% lidocaine for attenuating the haemodynamic responses to tracheal intubation and extubation, and for reducing emergence cough and postoperative sore throat. We hypothesised that, because of its longer duration of action, ropivacaine would better attenuate the response at extubation.
MATERIALS AND METHODS
Study design and ethics This prospective, randomised, double-blind study was conducted at the Institute of Anaesthesiology and Critical Care, Madras Medical College and Rajiv Gandhi Government General Hospital, Chennai, India, from March to December 2021. The protocol was approved by the Institutional Ethics Committee of Madras Medical College on 2 February 2021 (approval no. 09022021; EC Reg. No. ECR/270/Inst./TN/2013/RR-16). Written informed consent was obtained from all patients. Participants We included patients aged 18–65 years, of American Society of Anesthesiologists (ASA) physical status I or II, scheduled for elective surgery of less than 2 hours under general anaesthesia with tracheal intubation. Exclusion criteria were risk factors for pulmonary aspiration, chronic obstructive pulmonary disease or asthma, an anticipated difficult airway, recent respiratory tract infection, uncontrolled hypertension or diabetes, ischaemic heart disease, renal or hepatic disease, treatment with α- or β-blockers, and allergy to the study drugs. Sample size Sample size was based on the study by Thangavelu et al. [25], who reported heart rates at extubation of 96.4 ± 9.97 beats/min with nebulised ropivacaine and 103.72 ± 10.36 beats/min with nebulised lidocaine (mean ± standard deviation). With a two-sided α of 0.05 and 80% power, 30 patients were required in each group. Randomisation, blinding and intervention An independent statistician generated the random sequence by computer, with 1:1 allocation in variable blocks of 4 and 6. Allocation was concealed in sequentially numbered, opaque, sealed envelopes, opened only after enrolment and consent. A person not involved in recruitment or outcome assessment prepared both drugs in identical coded nebuliser containers. Patients, the anaesthesiologist administering anaesthesia, the outcome assessor and the data recorder were unaware of group allocation. Group R received 5 mL of 0.5% ropivacaine (25 mg) and Group L 5 mL of 2% lidocaine (100 mg), nebulised with 100% oxygen at 10 L/min through a face mask, with the patient propped up and breathing normally, until the full volume had been aerosolised (about 10 minutes). The study flow is shown in Fig. 1. Anaesthesia protocol Standard monitoring was used, and baseline values (T1) were recorded before nebulisation. After nebulisation, patients were preoxygenated and received glycopyrronium 10 µg/kg and fentanyl 2 µg/kg. Anaesthesia was induced with thiopental 5 mg/kg or propofol 2 mg/kg, and intubation was facilitated with atracurium 0.5 mg/kg. Anaesthesia was maintained with sevoflurane in 33% oxygen and 66% nitrous oxide, with maintenance doses of atracurium, with paracetamol 15 mg/kg for analgesia. At the end of surgery sevoflurane was stopped (T3). After return of spontaneous respiration, neuromuscular block was reversed with neostigmine 0.05 mg/kg and glycopyrronium 0.01 mg/kg, and the trachea was extubated when the patient obeyed commands and breathed regularly. Outcome measures Heart rate (HR), systolic (SBP), diastolic (DBP) and mean arterial pressure (MAP) were recorded at baseline (T1), tracheal intubation (T2), anaesthetic withdrawal (T3), eye opening to verbal command (T4), tracheal extubation (T5) and 2 minutes after extubation (T6), and at 30 and 60 minutes of surgery. The primary outcome was the haemodynamic response to intubation and extubation; secondary outcomes were cough at extubation, postoperative sore throat and intraoperative haemodynamics. Cough was graded as mild (a single cough), moderate (more than one unsustained cough lasting less than 5 seconds) or severe (sustained coughing for 5 seconds or more). Sore throat was recorded as present or absent at 12 hours. Laryngoscopy duration and Cormack–Lehane grade were noted. Hypotension (MAP decrease ≥ 30% from baseline) and bradycardia (HR < 50 beats/min) were to be treated with ephedrine 6 mg and atropine 0.6 mg, respectively. Statistical analysis Continuous variables were not normally distributed (Kolmogorov–Smirnov test) and are presented as median (interquartile range); they were compared with the Mann–Whitney U test. Categorical variables are presented as number (%) and were compared with the chi-square test or Fisher’s exact test, as appropriate. Differences in the proportions of patients with cough and sore throat are given with 95% confidence intervals (CI) calculated with the Newcombe hybrid score method. A p value < 0.05 was considered significant. Analyses were performed with IBM SPSS Statistics, version 26 (IBM Corp., Armonk, NY, USA).
RESULTS
Patient characteristics All 60 randomised patients received the allocated intervention and were analysed (Fig. 1). Age, sex, ASA physical status and duration of surgery did not differ between groups, although Group R was somewhat older (median 40 vs 28.5 years; p = 0.090; table 1). Laryngoscopy duration (median 18 vs 19 seconds) and Cormack–Lehane grade (grade I in 73.3% vs 70.0%; no grade III or IV) were similar, indicating comparable laryngoscopic conditions. As a double-blind randomised trial, this study provides level II evidence. Table 1. Patient characteristics Characteristic Group R (n = 30) Group L (n = 30) p value Age (years) 40 (25–54) 28.5 (22.8–40.5) 0.090 Sex, male/female (n) 10/20 8/22 0.573 ASA physical status I/II (n) 13/17 17/13 0.302 Duration of surgery (min) 77.5 (60–91.3) 77.5 (60–90) 0.911 Laryngoscopy duration (s) 18 (15–22) 19 (16–23) p Cormack–Lehane grade I/II (n) 22/8 21/9 0.774 Note: values are median (interquartile range) or number of patients. Age, duration of surgery and laryngoscopy duration, Mann–Whitney U test; sex, ASA physical status and Cormack–Lehane grade, chi-square test. No patient had Cormack–Lehane grade III or IV. ASA, American Society of Anesthesiologists; Group L, nebulised 2% lidocaine; Group R, nebulised 0.5% ropivacaine. Haemodynamic responses to intubation and extubation Baseline values did not differ between groups. At intubation (T2), all four variables were lower in Group L than in Group R (median HR 70 vs 79 beats/min, p < 0.001; SBP 118 vs 123 mmHg, p = 0.001; DBP 68 vs 72 mmHg, p = 0.006; MAP 84.5 vs 90 mmHg, p = 0.003; tables 2 and 3). None differed at anaesthetic withdrawal (T3) or eye opening (T4). At extubation (T5), all four were lower in Group R (HR 84 vs 88 beats/min, p = 0.038; SBP 131.5 vs 135 mmHg, p = 0.010; DBP 80 vs 84.5 mmHg, p = 0.003; MAP 97 vs 101 mmHg, p = 0.005), and the difference persisted 2 minutes later (T6: HR 86 vs 90 beats/min, SBP 132 vs 139 mmHg, DBP 79.5 vs 86 mmHg, MAP 97.5 vs 103.5 mmHg; all p < 0.001). Table 2. Heart rate (beats/min) and systolic blood pressure (mmHg) at each time point Time point HR, Group R HR, Group L p SBP, Group R SBP, Group L p T1 Baseline 83 (74.8–88) 78 (73.5–82) 0.101 125 (118.8–131.8) 128 (124–130) 0.365 T2 Intubation 79 (70–84.3) 70 (65–72) <0.001 123 (119.5–128.5) 118 (110–120) 0.001 T3 Withdrawal 76 (72–80) 75 (72–78) 0.397 123 (117.8–128.3) 122 (120–125) 0.778 T4 Eye opening 79.5 (77.5–80.5) 78 (78–82.5) 0.964 127 (122.8–130) 128 (125–129) 0.247 T5 Extubation 84 (80–88) 88 (83.5–90) 0.038 131.5 (127.5–135) 135 (132–136.3) 0.010 T6 2 min after 86 (81.5–89.3) 90 (86–94.3) <0.001 132 (125.8–138) 139 (135–140) <0.001 Note: values are median (interquartile range); n = 30 per group; Mann–Whitney U test. Group L, nebulised 2% lidocaine; Group R, nebulised 0.5% ropivacaine; HR, heart rate; SBP, systolic blood pressure; T1, baseline; T2, tracheal intubation; T3, anaesthetic withdrawal; T4, eye opening to verbal command; T5, tracheal extubation; T6, 2 minutes after extubation. Table 3. Diastolic and mean arterial pressure (mmHg) at each time point Time point DBP, Group R DBP, Group L p MAP, Group R MAP, Group L p T1 Baseline 74 (68–84.3) 76 (74–80.5) 0.343 90.5 (85–100.3) 93 (91–97) 0.248 T2 Intubation 72 (68.8–78) 68 (65–70) 0.006 90 (85.8–93.5) 84.5 (81–87) 0.003 T3 Withdrawal 74 (69.8–79.3) 74 (70–75) 0.494 90 (84.8–95.3) 90 (86.8–92) 0.710 T4 Eye opening 76 (72.8–80) 78 (75.8–79) 0.239 93 (88.8–96.3) 95 (92–96) 0.230 T5 Extubation 80 (75–83.3) 84.5 (80–86) 0.003 97 (92.8–100) 101 (97–103) 0.005 T6 2 min after 79.5 (74.8–84.5) 86 (84.8–88) <0.001 97.5 (91–101.5) 103.5 (100.8–105.3) <0.001 Note: values are median (interquartile range); n = 30 per group; Mann–Whitney U test. DBP, diastolic blood pressure; Group L, nebulised 2% lidocaine; Group R, nebulised 0.5% ropivacaine; MAP, mean arterial pressure; T1, baseline; T2, tracheal intubation; T3, anaesthetic withdrawal; T4, eye opening to verbal command; T5, tracheal extubation; T6, 2 minutes after extubation. Intraoperative haemodynamics and adverse events At 30 minutes of surgery, HR and SBP were slightly lower in Group L (median HR 68 (64–70) vs 71 (69.5–75) beats/min, p < 0.001; SBP 114 (108–118) vs 118 (110–120) mmHg, p = 0.046), whereas DBP (p = 0.225) and MAP (p = 0.058) did not differ. No variable differed at 60 minutes (all p > 0.05). No patient developed hypotension or bradycardia requiring treatment, and no other adverse events were recorded. Cough and sore throat Cough at extubation occurred in 6 patients (20%) in Group R and 15 (50%) in Group L (difference 30.0 percentage points, 95% CI 5.8 to 49.8; p = 0.015). Among patients who coughed, severity did not differ (p = 1.00): cough was severe in 1 of 6 in Group R and 4 of 15 in Group L. Sore throat at 12 hours occurred in 2 patients (6.7%) in Group R and 12 (40%) in Group L (difference 33.3 percentage points, 95% CI 12.1 to 51.7; p = 0.005; table 4). Table 4. Cough at extubation and postoperative sore throat Outcome Group R (n = 30) Group L (n = 30) p value Cough at extubation 6 (20.0%) 15 (50.0%) 0.015 Mild 4 8 Moderate 1 3 1.00* Severe 1 4 Sore throat at 12 h 2 (6.7%) 12 (40.0%) 0.005 Note: values are number of patients (%) or number of patients. Cough, chi-square test; sore throat, Fisher’s exact test; * cough severity among patients who coughed, Fisher’s exact test. Group L, nebulised 2% lidocaine; Group R, nebulised 0.5% ropivacaine.
DISCUSSION
In this trial, lidocaine better blunted the response to intubation, and ropivacaine the response to extubation. This timing fits the pharmacology of the two drugs. Lidocaine has a rapid onset, so airway anaesthesia was well established at intubation, about 10–15 minutes after nebulisation, but its effect had largely worn off by the end of surgery, typically more than an hour later. Ropivacaine has a slower onset and longer duration [23], so its effect at intubation was weaker but persisted to emergence. Dose may also have contributed: Group L received 100 mg of lidocaine and Group R only 25 mg of ropivacaine, and absorbed lidocaine may have had some systemic effect, although only part of a nebulised dose is absorbed [19]. Our extubation findings agree with recent studies of airway ropivacaine. Nebulised 0.75% ropivacaine attenuated HR at intubation and extubation compared with saline [26], laryngotracheal ropivacaine before intubation lowered blood pressure after intubation [18], and a multimodal regimen including laryngotracheal ropivacaine reduced emergence cough [5]. Thangavelu et al. found no significant difference between 0.25% ropivacaine and 2% lidocaine at extubation, although values were lower with ropivacaine [25]; the higher concentration we used may explain our clearer effect. Conversely, Geetha et al. found 0.75% ropivacaine superior to lidocaine even at nasotracheal intubation [27], suggesting that a higher ropivacaine concentration might also improve the intubation response. Nebulised lidocaine has been less effective than intravenous dexmedetomidine early after intubation [22], consistent with its modest, short-lived effect. Coughing at emergence stimulates the haemodynamic response, so the lower cough rate with ropivacaine probably contributed to the lower values at extubation. Topical airway anaesthesia reduces emergence cough [16, 17], and in meta-analyses systemic agents such as dexmedetomidine, remifentanil and intravenous lidocaine all reduce moderate to severe cough [4, 13], although dexmedetomidine causes more sedation and bradycardia than lidocaine [15]. The 40% incidence of sore throat with lidocaine is in line with pooled estimates after tracheal intubation [6], whereas the 6.7% with ropivacaine compares favourably with other nebulised preventive agents [20]; less coughing and continued mucosal anaesthesia probably both contributed. This study has limitations. It was a single-centre trial with 30 patients per group. The drugs were not given at equipotent doses, and only one concentration of each was studied. Two induction agents were allowed, and Group R was somewhat older. We did not measure plasma local anaesthetic concentrations, and there was no saline control group.
CONCLUSION
The choice of nebulised local anaesthetic for short elective surgery can be matched to the phase of anaesthesia at greatest risk. A single pre-induction dose of 2% lidocaine gave better haemodynamic control during tracheal intubation, while 0.5% ropivacaine gave a smoother emergence, with fewer patients coughing at extubation or reporting sore throat afterwards. Trials of equipotent doses and higher ropivacaine concentrations should test whether one agent can protect both phases.
REFERENCES
1. Mahiswar AP, Dubey PK, Ranjan A. Comparison between dexmedetomidine and fentanyl bolus in attenuating the stress response to laryngoscopy and tracheal intubation: a randomized double-blind trial. Braz J Anesthesiol. 2022;72(1):103-9. doi: 10.1016/j.bjane.2021.02.060. 2. Qin J, He C, Chen Z, Yan S, Ma J. Effects of intravenous lignocaine on haemodynamic responses to laryngoscopy and tracheal intubation in adults under general anaesthesia: a systematic review and meta-analysis. Indian J Anaesth. 2025;69(8):748-58. doi: 10.4103/ija.ija_201_25. 3. Russotto V, Myatra SN, Laffey JG, Tassistro E, Antolini L, Bauer P, et al. Intubation practices and adverse peri-intubation events in critically ill patients from 29 countries. JAMA. 2021;325(12):1164-72. doi: 10.1001/jama.2021.1727. PMID: 33755076. 4. Tung A, Fergusson NA, Ng N, Hu V, Dormuth C, Griesdale DEG. Medications to reduce emergence coughing after general anaesthesia with tracheal intubation: a systematic review and network meta-analysis. Br J Anaesth. 2020;124(4):480-95. doi: 10.1016/j.bja.2019.12.041. PMID: 32098647. 5. Xu J, Sun P, Ma JH, Wang DX. Multimodal prevention of emergence cough following nasal endoscopic surgery under general anesthesia: a double-blind randomized trial. Front Med (Lausanne). 2024;11:1288978. doi: 10.3389/fmed.2024.1288978. 6. Moulder ZJ, Mann J, Bramley P, Heinz J, Wiles MD. Postoperative sore throat: a systematic review. Anaesthesia. 2025. doi: 10.1111/anae.70048. Epub ahead of print. 7. Mazzotta E, Soghomonyan S, Hu LQ. Postoperative sore throat: prophylaxis and treatment. Front Pharmacol. 2023;14:1284071. doi: 10.3389/fphar.2023.1284071. 8. Chen Z, Zuo Z, Zhang L, Gong M, Ye Y, Jin Y, et al. Postoperative sore throat after tracheal intubation: an updated narrative review and call for action. J Pain Res. 2025;18:2285-306. doi: 10.2147/JPR.S498933. 9. Zou Y, Kong G, Wei L, Ling Y, Tang Y, Zhang L, et al. The effect of intravenous lidocaine on hemodynamic response to endotracheal intubation during sufentanil-based induction of anaesthesia. Anaesthesiol Intensive Ther. 2020;52(4):289-93. doi: 10.5114/ait.2020.99918. PMID: 33165879. 10. Kumar NRR, Jonnavithula N, Padhy S, Sanapala V, Naik VV. Evaluation of nebulised dexmedetomidine in blunting haemodynamic response to intubation: a prospective randomised study. Indian J Anaesth. 2020;64(10):874-9. doi: 10.4103/ija.IJA_235_20. 11. Misra S, Behera BK, Mitra JK, Sahoo AK, Jena SS, Srinivasan A. Effect of preoperative dexmedetomidine nebulization on the hemodynamic response to laryngoscopy and intubation: a randomized control trial. Korean J Anesthesiol. 2021;74(2):150-7. doi: 10.4097/kja.20153. 12. Grover N, Taneja R, Rashid Y, Shrivastava N. Nebulised fentanyl, dexmedetomidine and magnesium sulphate for attenuation of haemodynamic response to laryngoscopy and tracheal intubation: a double-blinded, randomised comparative study. Indian J Anaesth. 2023;67(8):730-5. doi: 10.4103/ija.ija_397_22. 13. Yang SS, Wang NN, Postonogova T, Yang GJ, McGillion M, Beique F, et al. Intravenous lidocaine to prevent postoperative airway complications in adults: a systematic review and meta-analysis. Br J Anaesth. 2020;124(3):314-23. doi: 10.1016/j.bja.2019.11.033. PMID: 32000978. 14. Fan X, Cai H, Pan B, Xie Y. Comparison of dexmedetomidine and remifentanil on reducing coughing during emergence from anesthesia with tracheal intubation: a meta-analysis. Front Pharmacol. 2022;13:993239. doi: 10.3389/fphar.2022.993239. 15. Purohit A, Kumar M, Kumar N, Bindra A, Pathak S, Yadav A. Comparison between dexmedetomidine and lidocaine for attenuation of cough response during tracheal extubation: a systematic review and meta-analysis. Indian J Anaesth. 2024;68(5):415-25. doi: 10.4103/ija.ija_790_23. 16. Sakae TM, Souza RLP, Brandão JCM. Impact of topical airway anesthesia on immediate postoperative cough/bucking: a systematic review and meta-analysis. Braz J Anesthesiol. 2023;73(1):91-100. doi: 10.1016/j.bjane.2021.03.016. PMID: 33895219. 17. Chen ZX, Shi Z, Wang B, Zhang Y. Intracuff alkalinized lidocaine to prevent postoperative airway complications: a meta-analysis. World J Clin Cases. 2021;9(34):10626-37. doi: 10.12998/wjcc.v9.i34.10626. PMID: 35004994. 18. Niu J, Hu R, Yang N, He Y, Sun H, Ning R, et al. Effect of intratracheal dexmedetomidine combined with ropivacaine on postoperative sore throat: a prospective randomised double-blinded controlled trial. BMC Anesthesiol. 2022;22(1):144. doi: 10.1186/s12871-022-01694-6. 19. Vora J, Leslie D, Stacey M. Awake tracheal intubation. BJA Educ. 2022;22(8):298-305. doi: 10.1016/j.bjae.2022.03.006. 20. Yu J, Ren L, Min S, Yang Y, Lv F. Nebulized pharmacological agents for preventing postoperative sore throat: a systematic review and network meta-analysis. PLoS One. 2020;15(8):e0237174. doi: 10.1371/journal.pone.0237174. 21. Nabil F, Gharib AA, Gadelrab NA, Osman HM. Preoperative lignocaine nebulisation for attenuation of the pressor response of laryngoscopy and tracheal intubation in patients with severe preeclampsia undergoing caesarean section delivery: a randomised double-blind controlled trial. Indian J Anaesth. 2023;67(6):515-22. doi: 10.4103/ija.ija_898_22. 22. Sriramka B, Warsi ZH, Sahoo J. Effects of adding dexmedetomidine to nebulized lidocaine on control of hemodynamic responses to laryngoscopy and intubation: a randomized clinical trial. J Anaesthesiol Clin Pharmacol. 2023;39(1):11-7. doi: 10.4103/joacp.JOACP_93_21. PMID: 37250266. 23. Maqusood S, Madavi S, Bele A, Dash S, Bawiskar D. Pharmacological insights of ropivacaine and clinical applications: a narrative review. Cureus. 2024;16(8):e67565. doi: 10.7759/cureus.67565. 24. Shankar S, Chakole V. Ropivacaine: a review on the pharmacological features, therapeutic efficacy and side-effects when used for caudal epidural analgesia. J Clin Diagn Res. 2022;16(8):UE01-4. doi: 10.7860/JCDR/2022/56478.16687. 25. Thangavelu R, Ventakesh RR, Ravichandran K. Comparison of effect of airway nebulization with lignocaine 2% versus ropivacaine 0.25% on intubation and extubation response in patients undergoing surgery under general anesthesia: a randomized double-blind clinical trial. Anesth Essays Res. 2018;12(2):338-43. doi: 10.4103/aer.AER_83_18. PMID: 29962594. 26. Saxena P, Gill RK, Saroa R, Sidhu B, Alen J, Sood P. Comparison of nebulized ropivacaine (0.75%) with nebulized dexmedetomidine on the hemodynamic response on intubation in patients undergoing surgery under general anesthesia: a comparative randomized double-blind placebo-controlled study. Saudi J Anaesth. 2024;18(1):31-9. doi: 10.4103/sja.sja_391_23. PMID: 38313724. 27. Geetha S, Prashanth NVSSK, Durga P, Jayaram K, Farooq M, Chandra S, et al. Comparison of nebulisation 0.75% ropivacaine with 2% lignocaine for attenuation of haemodynamic response due to intubation: a prospective randomised study. J Perioper Pract. 2024 Apr 10. doi: 10.1177/17504589241229906. PMID: 38600632. Epub ahead of print.
Recommended Articles
Original Article
Short-term outcomes of preterm births: a prospective cohort study at a tertiary care hospital in South India
...
Published: 20/11/2026
Original Article
Three-Month Functional Recovery After Primary Total Knee Arthroplasty for Advanced Osteoarthritis: An Educational Cohort Analysis of Patient-Reported and Clinical Outcomes
Published: 28/08/2026
Original Article
Association of Perceived Academic Stress with Cardiac Autonomic Function Among Undergraduate Medical Students: A Heart Rate Variability Study
Published: 27/12/2025
Original Article
A Study Of The Clinicopathological Profile Of Oral Cavity Malignancies In A Tertiary Care Centre
Published: 30/12/2023
Chat on WhatsApp
© Copyright Journal of Contemporary Clinical Practice